SCHEMBL4635925

SCHEMBL4635925

N#Cc1ccc(N2CC3C(N)C3C2)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.47
DPP8 Q6V1X1 2/20 0.47
DPP9 Q86TI2 2/20 0.47
DPP7 Q9UHL4 2/20 0.47
CHRM2 P08172 1/20 0.40
TRPA1 O75762 1/20 0.40
CHRM4 P08173 2/20 0.38
SLC6A9 P48067 7/20 0.38
ADRA1D P25100 1/20 0.38
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
AOC3 Q16853 2/20 0.37
SLC6A5 Q9Y345 2/20 0.36
USP30 Q70CQ3 1/20 0.36
PARP1 P09874 2/20 0.36
PARP2 Q9UGN5 2/20 0.36
PIM2 Q9P1W9 1/20 0.36
PREP P48147 1/20 0.35
KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4635559 0.82 DPP4 (0.47) DPP4DPP8DPP9DPP7PARP1
SCHEMBL22210151 0.81 DPP4 (0.45) DPP4DPP8DPP9DPP7CHRM2
SCHEMBL4635265 0.81 DPP4 (0.50) DPP4DPP8DPP9DPP7AOC3
SCHEMBL4470692 0.79 EPHA2 (0.47) DPP4DPP9CHRM4ADRA1DADRA1A
SCHEMBL3965681 0.79 EPHA2 (0.47) DPP4DPP9CHRM4ADRA1DADRA1A
SCHEMBL250260 0.78 DPP4 (0.42) DPP4DPP8DPP9DPP7CHRM2
SCHEMBL250187 0.78 ALDH1A1 (0.50) DPP4DPP8DPP9DPP7CHRM2
SCHEMBL4635237 0.77 DPP4 (0.47) DPP4DPP8DPP9CHRM4
SCHEMBL15117102 0.74 SLC6A9 (0.57) SLC6A9ADRA1DADRA1AADRA1BSLC6A5
SCHEMBL4895815 0.74 HRH3 (0.49) DPP4DPP8DPP9DPP7PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors RANBAXY LABORATORIES LIMITED (IN) 2008-12-04 US disclosed
EP-1931633-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS Ranbaxy Laboratories Limited (IN) 2008-06-18 EP disclosed
WO-2007029086-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP8 DPP4 1/4885DPP8 3/4885DPP9 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.